MERTK and non-small cell lung carcinoma: More importantly, Mer expression dictates the response to EGFR-targeted small-molecule inhibitor of NSCLC cells with EGFR gene mutation, warranting further investigation of Mer inhibitors as potential therapeutic agents in NSCLC.